Medherant New Appointments (September 2023)

Medherant appoints Karolina Afors as Medical Director and Fran Crawford joins as a non-executive director

11 September 2023 (Coventry, UK). Medherant announces that Dr Karolina Afors BSC MBBS MRCOG has joined the company in the newly-created role of Medical Director to lead the clinical development of the company’s testosterone patch for post-menopausal women and other product development opportunities. Dr Afors is a consultant obstetrician & gynaecologist with over 15 years of experience in NHS and private practice.

“I have an avid interest in the menopause and am passionate about finding solutions for women’s health through innovation in new technologies,” says Dr Afors on joining Medherant’s management team.

Dr Francesca Crawford has recently been appointed as a non-executive director of Medherant Limited. Fran is CEO of Somaserve Limited and has extensive experience in pharmaceutical R&D, and executive management and funding of research and development-stage biotech companies.

“I am delighted to have joined Medherant’s board at this exciting time as the first product enters the clinic. I look forward to contributing to the ongoing development and commercialisation strategy of the pipeline and to building success in the important area of women’s health. ”, says Fran Crawford on her appointment to Medherant’s board of directors.

“I am delighted that Karolina and Fran have joined Medherant as their experience significantly strengthens our team as we move our testosterone patch for post-menopausal women in the clinic and plan for its registration and commercialisation,” says John Burt, Medherant CEO.

About Medherant

Medherant Limited operates from the University of Warwick Science Park and has developed a novel, proprietary approach for development of patches to deliver medicines across the skin. The company was founded by University of Warwick’s Professor of Polymer Chemistry, Professor David Haddleton.

Medherant’s transdermal patch technology can create patches that are less irritant to patients, can provide higher drug doses and avoid leaving adhesive residue on patients’ skin.

In addition to developing its own products, Medherant collaborates with pharmaceutical companies in developing transdermal patch products for already approved drugs.

Medherant’s lead product is a testosterone patch for post-menopausal women, being developed to address the lack of an approved testosterone product for women despite the NICE Menopause Guidelines and Global Consensus Position Statement on the Use of Testosterone Therapy for Women.